Lv5
1306 积分 2025-02-28 加入
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
3天前
已完结
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study
3天前
已关闭
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers
5天前
已完结
Predictive Value of PIK3CA Mutations for Response to CDK4/6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
5天前
已完结
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients
5天前
已完结
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
11天前
已完结
Preparation and in vitro/in vivo evaluation of uniform-sized Goserelin-loaded sustained release microspheres
19天前
已完结
Goserelin/PLGA solid dispersion used to prepare long-acting microspheres with reduced initial release and reduced fluctuation of drug serum concentration in vivo
19天前
已完结
Clinical Pharmacokinetics of Depot Leuprorelin
20天前
已完结
Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy Use
20天前
已完结
皖公网安备34019202002308
